Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the combination regimen of Venclexta® (venetoclax) ...

At 33 years old, Kaedi Cecala faced […] ...

In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how ...

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY ...

A bride left wedding guests stunned and many in tears after revealing that the stem cell donor who saved her life was ...

Skidaway Island resident Bruce Koehler is among early participants seeing clinical blood‑count improvements in a nationwide prevention study ...

The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...

In AYAs, the ASH guideline panel recommends pediatric-inspired (asparaginase-containing) regimens for treatment-naïve B-ALL and T-ALL, and blinatumomab for relapsed/refractory B-ALL.

Researchers sought to determine whether reducing the induction daunorubicin dose among pediatric patients with low-risk B-cell ALL would compromise efficacy.

Moffitt Cancer Center is now out of reach for many with Aetna Medicare Advantage HMO and PPO plans, and it will soon be the same for Humana Medicare Advantage HMO and PPO plans.

By the time cancer symptoms appear, the disease has already been developing for years, often leaving subtle clues in routine bloodwork long before diagnosis.

The FDA approved protocol updates to a tasquinimod trial in myelofibrosis, allowing broader enrollment and combination use ...